Acute Myeloid Leukemia
Margaret R. O'Donnell(University of Alabama at Birmingham), Camille N. Abboud(University of Alabama at Birmingham), Jessica K. Altman(University of Alabama at Birmingham), F R Appelbaum, Daniel A. Arber, Eyal C. Attar(University of Alabama at Birmingham), Uma Borate, Steven Coutré(University of Alabama at Birmingham), L E Damon(University of Alabama at Birmingham), Salil Goorha, Jeffrey Lancet(University of Alabama at Birmingham), Lori J. Maness(University of Alabama at Birmingham), Guido Marcucci, Michael M. Millenson(University of Alabama at Birmingham), Joseph O. Moore, Farhad Ravandi(University of Alabama at Birmingham), Paul J. Shami(University of Alabama at Birmingham), B. Douglas Smith, Richard M. Stone(University of Alabama at Birmingham), Stephen A. Strickland(University of Alabama at Birmingham), Martin S. Tallman(University of Alabama at Birmingham), Eunice S. Wang(University of Alabama at Birmingham), Maoko Naganuma, Kristina M. Gregory
Cited by 326Open Access
Abstract
Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age ≥ 65 years) adult patients, and key supportive care considerations.